Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06440278
Other study ID # R34HL165716-01A1
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 2024
Est. completion date July 31, 2025

Study information

Verified date May 2024
Source The Miriam Hospital
Contact Emily Gathright, PhD
Phone 401-793-8271
Email Emily.Gathright@lifespan.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sixty adults who have experienced acute coronary syndrome within the past 2-12 months from three states (Rhode Island, North Carolina, Minnesota) will be randomized to either (1) a coaching program for depressed mood and health behavior change (Behavioral Activation for Health and Depression; BA-HD), or (2) Enhanced Usual Care. This study will evaluate the feasibility and acceptability of study procedures and BA-HD, and establish protocol and measurement harmonization across three sites in preparation for a future multi-site efficacy trial.


Description:

Acute coronary syndrome (ACS) represents a significant public health burden, with the most recent estimates suggesting that over 1 million U.S. adults experience ACS per year. As individuals are acutely surviving ACS more often, the associated disease burden is increasing for both the healthcare system and the individual living post-ACS. Poor engagement in health behaviors post-ACS contributes to risk for recurrent ACS and mortality. Modifiable behavioral contributors include smoking, medication non-adherence, physical inactivity, and poor diet. Approximately 20% of post-ACS adults experience depression and depression is associated with worse engagement in critical health behaviors, which in turn, increases subsequent progression of cardiovascular disease. Treatment of depression alone improves, but does not eliminate, behavioral nonadherence. Behavioral Activation is a robust counseling treatment for depression with evidence of improvements in depressive symptoms across varied populations (including those with medication conditions). BA seeks to improve mood by increasing environmental reinforcement through collaborative, values-guided setting of "activation goals." The goal setting focus and structure of BA allows for seamless integration of health behavior targets and thus offers a potential framework to integrate depression and health behavior treatment. BA-HD may be a useful strategy to depression and multiple health behavior improvement post-ACS. However, this possibility requires further testing. The purpose of this study is to examine the feasibility and acceptability of a multisite pilot randomized controlled trial and test the initial potential effects of the intervention (BA-HD) on cardiovascular health and depressive symptoms relative to an Enhanced Usual Care control condition. Participants will be randomly assigned to either 12 weeks of tele-delivered BA-HD) or Enhanced Usual Care (i.e., one session of depression and heart disease education and provision of community mental health resources). Primary endpoints are feasibility of multisite recruitment procedures (e.g., recruitment rates at each site), feasibility of intervention and control procedures (e.g., percent of enrolled participants who complete the study), study retention (e.g., percent of participants who complete 3 month follow-up), and acceptability of intervention content and intervention delivery and control procedures. We hypothesize that the intervention content and delivery will be 1) feasible and 2) acceptable. We will also examine changes in cardiovascular health, depressive symptoms, medication adherence, affect, and quality of life.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date July 31, 2025
Est. primary completion date April 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Medical chart-documented ACS (diagnosis of unstable angina, ST or non-ST elevation myocardial infarction) occurrence within the past 2-12 months. - Post-ACS depressed mood defined as a Patient Health Questionnaire(PHQ)--9 score = 10 upon screening, - Non-adherence to and willingness to implement changes to =1 health behavior based on screening of: 1. Smoking/Tobacco exposure, 2. Physical Activity, 3. Diet, 4. Sleep health, 5. Medication adherence - English-language fluency - Resides within 90 minutes (driving time) of each site with no plans to relocate beyond that range during study participation - Access to a telephone and/or videoconferencing capability - Has primary care provider - Address at which packages can be received Exclusion Criteria: - Chart indication of significant cognitive impairment (e.g., chart-documented dementia), Current exacerbation of serious mental illness, - Suicidality, - Hearing impairment that prevents telephone/video communication for intervention and assessment purposes, - Current hospice care, and - Current engagement in cardiac rehabilitation or other regular counseling treatment targeting depression or health behavior change

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Behavioral Activation for Health and Depression (BA-HD)
BA-HD includes 8 - 10 sessions delivered over 10-12 weeks. Sessions use behavioral activation techniques to connect patient core values with goal-setting targeting activities that improve mood, alongside personalized adjustments to cardiovascular health behaviors (i.e., tobacco cessation, medication adherence, physical activity, diet, and sleep). Educational materials and commercially available tools like activity trackers, pillboxes, and portion control aids will accompany the goal-setting process to facilitate behavior change.
Other:
Enhanced Usual Care
Patients will receive depression and heart disease education, as well as a list of local mental health resources.

Locations

Country Name City State
United States ECU Health Greenville North Carolina
United States Hennepin Healthcare Research Institute Minneapolis Minnesota
United States The Miriam Hospital Providence Rhode Island

Sponsors (1)

Lead Sponsor Collaborator
The Miriam Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recruitment feasibility Number of participants randomized per month of recruitment Baseline
Primary Study retention Proportion of randomized participants who complete the 6 month assessment. Week 26
Primary Treatment engagement Dose of treatment received (i.e., session attendance) Week 13
Primary Treatment Acceptability Client Satisfaction Questionnaire-8; Scores range from 8-32 with higher scores indicating greater treatment satisfaction. Week 13
Secondary Cardiovascular Health Life's Essential 8 (LE8) Score; The LE8 classifies cardiovascular (CV) health across eight CV risk metrics: diet, physical activity, nicotine exposure, sleep health, weight, blood pressure, total cholesterol, and hemoglobin A1C. Each individual LE8 component is assigned a value ranging from 0 to 100. A total score is created by averaging each component score. Higher total scores reflect better overall CV health. Week 13, Week 26
Secondary Depressive symptoms Patient Health Questionnaire-9; Scores range from 0 to 27; higher scores indicate greater depressive symptoms. Week 13, Week 26
Secondary 7 Day Moderate to Vigorous Physical Activity Minutes spent in moderate to vigorous physical activity from 7 day Actigraph wear Week 13, Week 26
Secondary Self-Reported Moderate to Vigorous Physical Activity Minutes spent in moderate to vigorous physical activity over 7 days based on report from a 7 Day Physical Activity Recall interview Week 13, Week 26
Secondary Self-Reported Diet Mediterranean Eating Pattern for Americans Questionnaire; Scores range from 0-16 with higher scores indicating greater consistency with mediterranean style diet Week 13, Week 26
Secondary 7-day point prevalence abstinence from smoking Self-report of no smoking, not even a puff, for 7 days; then Bio-chemically confirmed by carbon monoxide in a breath sample Week 13, Week 26
Secondary Sleep duration Average hours of sleep per night over 7 nights assessed via 7 day Actigraph wear Week 13, Week 26
Secondary Self-reported sleep duration Self-reported hours of sleep per night from the Pittsburgh Sleep Quality Index Week 13, Week 26
Secondary Body Mass Index Body weight (kilograms)/ Height (meters squared) Week 13, Week 26
Secondary Blood pressure Systolic and diastolic blood pressures (mmHg) Week 13, Week 26
Secondary Non-HDL cholesterol mg/dL; measured via point of care testing Week 13, Week 26
Secondary Hemoglobin A1C %; measured via point of care testing Week 13, Week 26
Secondary Medication adherence (cholesterol regimen) DOSE-Nonadherence Extent of Nonadherence items will be used to assess self-reported medication adherence to cholesterol medication; scores range from 1-5. Week 13, Week 26
Secondary Medication adherence (blood pressure regimen) DOSE-Nonadherence Extent of Nonadherence items will be used to assess self-reported medication adherence to blood pressure medication; scores range from 1-5 Week 13, Week 26
Secondary Medication adherence (blood glucose regimen) DOSE-Nonadherence Extent of Nonadherence items will be used to assess self-reported medication adherence to both oral and injectable medication (assessed separately) to manage blood glucose; scores range from 1-5 Week 13, Week 26
Secondary Major Adverse Cardiac Events Composite of hospitalization for unstable angina, urgent coronary revascularization, and non-fatal myocardial infarction determined via participant inquiry and confirmed through electronic medical record review Week 26
Secondary All-cause mortality Electronic medical record review Week 26
Secondary Health Behavior Engagement Composite A health behavior engagement composite score will be created that follows the LE8 scoring structure. LE8 component scores will be summed for physical activity, diet, combustible tobacco exposure, and sleep. Medication adherence will also be assigned a score ranging from 0 to 100 based on scaled DOSE-Nonadherence scores. Week 13, Week 26
See also
  Status Clinical Trial Phase
Recruiting NCT06013813 - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT05412927 - AngelMed Guardian® System PMA Post Approval Study
Completed NCT02750579 - Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes? N/A
Completed NCT04102410 - Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients N/A
Enrolling by invitation NCT03342131 - Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome N/A
Recruiting NCT01218776 - International Survey of Acute Coronary Syndromes in Transitional Countries
Enrolling by invitation NCT04676100 - International CR Registry
Completed NCT03590535 - 5th Generation cTnT in ED ACS
Recruiting NCT05437900 - INSIGHTFUL-FFR Clinical Trial Phase 4
Completed NCT05551429 - Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
Terminated NCT04316481 - IDE-ALERTS Continued Access Study N/A
Active, not recruiting NCT04475380 - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Not yet recruiting NCT04852146 - Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
Active, not recruiting NCT02892903 - In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes? N/A
Completed NCT02944123 - Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR) Phase 3
Not yet recruiting NCT02871622 - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM N/A
Completed NCT04077229 - Piloting Text Messages to Promote Positive Affect and Physical Activity N/A
Active, not recruiting NCT02922140 - The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit N/A
Completed NCT02673437 - Rivaroxaban ACS Specialist Cohort Event Monitoring Study